Metsera reports progress on clinical milestones and financial stability.

From GlobeNewswire: 2025-05-12 07:00:00

Metsera, Inc. is advancing MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist, in three ongoing Phase 2b VESPER trials, with data from VESPER-1 expected in mid-2025. MET-233i, a monthly amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week data expected in Q2 2025. MET-097o, an oral formulation of MET-097i, is progressing, with $588 million cash supporting operations into 2027.

Metsera reported first quarter 2025 financial results, highlighting progress on clinical milestones. MET-097i demonstrated weight loss and tolerability data, with Phase 3 initiation planned in late 2025. MET-233i is expected to release five-week monotherapy data in Q2 2025, with additional data in late 2025. MET-097o and MET-224o, oral formulations, are advancing, with four-week data expected in late 2025.

Financially, Metsera’s cash position was $588 million as of March 31, 2025, with sufficient funds to support operations into 2027. Research and development expenses were $57.2 million, driven by product candidate development costs. General and administrative expenses were $8.6 million, primarily due to personnel-related expenses. The net loss for the quarter was $76.6 million, with $54.3 million in net cash used in operating activities.

Metsera’s Amneal collaboration is progressing, with new facilities in India dedicated to peptide synthesis and sterile fill-finish manufacturing. Jon P. Stonehouse and Matthew Lang were appointed to key roles within the organization. Metsera continues to advance its portfolio of oral and injectable therapies for obesity and metabolic diseases, with a focus on innovative treatments for weight loss.



Read more at GlobeNewswire:: Metsera Reports First Quarter 2025 Financial Results and